Owner Investor / Financier Operator Developer
Merck & Co., Inc. (branded as MSD outside the United States and Canada) is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of human prescription medicines, vaccines, and biologic therapies. The company’s portfolio and pipeline span major therapeutic areas including oncology, infectious diseases, vaccines, cardiometabolic conditions, and immunology.
Merck also operates a substantial animal health business (Merck Animal Health/MSD Animal Health), providing veterinary pharmaceuticals, vaccines, and health management solutions for companion and production animals. The company maintains a worldwide network of research, clinical development, and manufacturing sites supporting small-molecule, biologics, and vaccine production.
Note: Merck & Co., Inc. (MSD) is distinct from Merck KGaA, Darmstadt, Germany, which operates separately and uses different branding in North America.
Also known as Merck Group, Merck KGaA, Darmstadt, Germany, Merck KGaA, MSD, and Merck Sharp & Dohme.
chemXplore tracks 9 projects involving Merck, of which 3 are active.
Besides these 3, the record holds 6 completed projects.
Closest to start-up first.
The 6 that are completed, on hold or cancelled are in the record. See all 9 in chemXplore →
Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.
Randomized Phase 3 will enroll ~2,136 adults on standard COPD therapy to test whether add-on ensifentrine reduces annualized moderate/severe exacerbation rate over 52 weeks.
Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.
Phase 3 KEYNOTE‑C93: pembrolizumab alone extended median PFS to 38.2 vs 8.4 months versus platinum doublet; results presented at ESMO and published in The Lancet.
Intismeran plus pembrolizumab cut risk of recurrence or death 42% overall and 58% after six months; distant‑metastasis‑free survival also improved; safety profile consistent.
EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
A $550 million R&D expansion adds automated robotics and AI to streamline clinical-sample analysis and support a broad clinical development pipeline.
Phase 3 intismeran combo improved recurrence‑free and distant metastasis‑free survival in resected stage IIB–IV melanoma; sac‑TMT and KEYNOTE‑C93 report pivotal endometrial cancer findings; >90 additional abstracts.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
